|
��չ����
|
|
| ������Ϣ | |
 |
Supporting info |
|
PDFȫ�� |
|
[HTMLȫ��] |
|
����� |
| �����뷴�� | |
|
�������ù����� |
|
���� |
|
Email Alert |
|
���·��� |
|
���������Ϣ |
| ���Ĺؼ���������� | |
|
ӲƤ��,������ |
|
���� |
|
ҩ���Ʒ� |
|
��Ѫ��ϸ����ֲ |
| ��������������� | |
|
��� |
|
�ƽ��� |
| PubMed | |
|
Article by |
|
Article by |
ӲƤ�����Ƶ��о���չ
�γ���, �ƽ���
���ϴ�ѧ������ҽԺƤ����, ��ɳ410013
ӲƤ���������Ʋ���,�������ѡ����������о���ʾ�ǻ���������������⻯ѧ�Ʒ��Լ��װ����ʵȿ��������ƾ�����ӲƤ����ͬʱ�ڲ����µ�Ѫ�����ż����������Ƽ�������⻯ѧ�Ʒ��������ϸ����ֲ�����Ʒ�����ϵͳ��ӲƤ������Ҳȡ����һ���Ľ�չ��
[2] Hulshof MM, Bouwes Bavinck JN, Bergman W, et al. Double-blind,placebo-controlled study of oral calcitriol for the treatment of localized and systemic scleroderma. J Am Acad Dermatol, 2000, 43:1017-1023.
[3] Cunningham BB, Landells ID, Langman C, et al. Topical calcipotriene for morphea/linear scleroderma. J Am Acad Dermatol,1998, 39(2 Pt 1):211-215.
[4] Kreuter A, Gambichler T, Avermaete A, et al. Combined treatment with calcipotriol ointment and low-dose ultraviolet A1 phototherapy in childhood morphea. Pediatr Dermatol, 2001, 18:241-245.
[5] Tay YK. Topical calcipotriol ointment in the treatment of morphea. J Dermatolog Treat, 2003, 14:219-221.
[6] Kerscher M, Meurer M, Sander C,et al. PUVA bath photochemotherapy for localized scleroderma. Evaluation of 17 consecutive patients. Arch Dermatol, 1996, 132:1280-1282.
[7] Kerscher M, Volkenandt M, Gruss C, et al. Low-dose UVA phototherapy for treatment of localized scleroderma. J Am Acad Dermatol, 1998, 38:21-26.
[8] Gruss C, Reed JA, Altmeyer P, et al. Induction of interstitial collagenase (MMP-1) by UVA-1 phototherapy in morphea fibroblasts.Lancet, 1997, 350:1295-1296.
[9] Seyger MM, van den Hoogen FH, de Boo T, et al. Low-dose methotrexate in the treatment of widespread morphea. J Am Acad Dermatol, 1998, 39(2 Pt 1):220-225.
[10] Uziel Y, Feldman BM, Krafchik BR, et al. Methotrexate and corticosteroid therapy for pediatric localized scleroderma. J Pediatr,2000, 136:91-95.
[11] Wigley FM, Korn JH, Csuka ME, et al. Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis:a multicenter, placebo-controlled, double-blind study. Arthritis Rheum, 1998, 41:670-677.
[12] Scorza R, Caronni M, Mascagni B, et al. Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud's phenomenon.A randomized, controlled study. Clin Exp Rheumatol, 2001, 19:503-508.
[13] Stratton R, Shiwen X, Martini 3, et al. Iloprost suppresses connective tissue growth factor production in fibroblasts and in the skin of scleroderma patients. J Clin Invest, 2001, 108:241-250.
[14] Channick RN, Simonneau G, Sitbon O,et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension:a randomised placebo-controlled study. Lancet, 2001,358:1119-1123.
[15] Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med, 2002, 346:896-903.
[16] Badesch DB, Tapson VF, McGoon MD,et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med, 2000, 132:425-434.
[17] Pope JE, Bellamy N, Seibold JR, et al. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma.Arthritis Rheum, 2001, 44:1351-1358.
[18] Varai G, Earle L, Jimenez SA, et al. A pilot study of intermittent intravenous cyclophosphamide for the treatment of systemic sclerosis associated lung disease. J Rheumatol, 1998, 25:1325-1329.
[19] Davas EM, Peppas C, Maragou M, et al. Intravenous cyclophosphamide pulse therapy for the treatment of lung disease associated with scleroderma. Clin Rheumatol, 1999,18:455-461.
[20] White B, Moore WC, Wigley FM, et al. Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med, 2000, 132:947-954.
[21] Pakas ��, Ioannidis JP, Malagari K, et al. Cyclophosphamide with low or high dose prednisolone for systemic sclerosis lung disease. J Rheumatol, 2002, 29:298-304.
[22] Griffiths B, Miles S, Moss H, et al. Systemic sclerosis and interstitial lung disease:a pilot study using pulse intravenous methylprednisolone and cyclophosphamide to assess the effect on high resolution computed tomography scan and lung function. J Rheumatol,2002, 29:2371-2378.
[23] Filaci G, Cutolo M, Scudeletti M, et al. Cyclosporin A and iloprost treatment of systemic sclerosis:clinical results and interleukin-6serum changes after 12 months of therapy. Rheumatology (Oxford),1999, 38:992-996.
[24] Basso M, Filaci G, Cutolo M, et al. Long-term treatment of patients affected by systemic sclerosis with cyclosporin A. Ann Ital Med Int,2001,16:233-239.
[25] Muellegger RR, Hofer A, Salmhofer W, et al. Extended extracorporeal photochemotherapy with extracorporeal administration of 8-methoxypsoralen in systemic sclerosis. An Austrian single-center study. Photodermatol Photoimmunol Photomed, 2000, 16:216-223.
[26] Martini A, Maccario R, Ravelli A, et al. Marked and sustained improvement 2 years after autologous stem cell transplantation in a girl with systemic sclerosis. Rheumatology(Oxford), 1999, 38:773.
[27] Binks M, Passweg JR, Furst D, et al. Phase ��/�� trial of autologous stem cell transplantation in systemic sclerosis:procedure related mortality and impact on skin disease. Ann Rheum Dis, 2001, 60:577-584.